Introduction {#s1}
============

Eukaryotic lysosomes are acidic, membrane-bound organelles that contain proteases, lipases and nucleases and degrade cellular components to regenerate catabolic precursors for cellular use ([@bib32]; [@bib26]; [@bib24]). Lysosomes are crucial for the degradation of substrates from the cytoplasm, as well as membrane bound compartments derived from the secretory, endocytic, autophagic and phagocytic pathways. The limiting membrane of lysosomes is lined with so-called lysosomal membrane glycoproteins (LAMPs) that are comprised of a short cytoplasmic domain, a single transmembrane span, and a highly, N- and O-glycosylated lumenal domain ([@bib31]; [@bib14]; [@bib8]). Because of their abundance and glycan content, LAMPs have been proposed to serve as a protective barrier to block hydrolase access to the limiting phospholipid bilayer. LAMP1 and LAMP2 are 37% identical and may overlap in function, but knockout of LAMP1 in mouse has a much milder phenotype than depletion of LAMP2 ([@bib28]): LAMP2-deficient mice have very short lifespans, and show massive accumulation of autophagic structures in most tissues. Indeed, LAMPs are required for fusion of lysosomes with phagosomes ([@bib11]) and LAMP2 has also been proposed to serve as a receptor for chaperone-mediated autophagy ([@bib3], [@bib4]; [@bib2]).

Previous work has implicated LAMP2 in cholesterol export from lysosomes, as LAMP-deficient cells show cholesterol accumulation that can be rescued by LAMP2 expression ([@bib5]; [@bib25]). Proteome-wide analysis of cholesterol binding proteins included LAMP1 and LAMP2 among a long list of candidate proteins ([@bib10]). Despite these hints, the precise function of LAMP proteins has remained unclear, and they are often presumed to be structural components. We show here that LAMP proteins bind cholesterol directly and this capacity contributes to their role in cholesterol export from lysosomes.

Results and discussion {#s2}
======================

We sought to verify direct cholesterol binding to LAMP proteins using LAMP protein lumenal domains, engineered to be secreted from cells by simple deletion of their transmembrane and short cytoplasmic domains ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [Figure 1A](#fig1){ref-type="fig"}). Soluble, purified, LAMP1 and LAMP2 proteins appeared to bind ^3^H-cholesterol saturably, at a stoichiometry comparable to equimolar amounts of purified, NPC1 N-terminal domain (NTD) that contains a single cholesterol binding site ([@bib12]; [@bib15]; [Figure 1B,D,E](#fig1){ref-type="fig"}) (note that this does not provide information about relative binding affinities). Binding was not especially sensitive to pH ([Figure 1H](#fig1){ref-type="fig"}) and was complete after \~2 hr at 4°C ([Figure 1I](#fig1){ref-type="fig"}).10.7554/eLife.21635.003Figure 1.Cholesterol binding to LAMP proteins.(**A**) Coomassie-stained SDS-PAGE of purified, secreted human LAMP1, LAMP2 or LAMP domains from LAMP2. **B**,**C**. ^3^H-cholesterol or ^3^H-25 hydroxycholesterol binding to soluble LAMP2 (full length protein). Also shown in **C** is binding in the presence of 50 µM cold hydroxycholesterol. **D**,**E**, ^3^H-cholesterol binding to indicated, soluble proteins compared with the soluble NPC1 N-terminal domain. (**F**), Cholesterol binding to LAMP2 domains 1 and 2 compared with full length, soluble LAMP2 protein. P values were determined relative to the full length soluble LAMP2 protein. (**G**) Sterol competition (30 µM) for ^3^H-cholesterol binding to soluble LAMP2. P values were determined relative to no cold addition. **H**, **I**. pH dependence and kinetics of ^3^H-cholesterol binding to LAMP2. In **B**,**C**,**E**,**H** and **I**, a representative experiment is shown; **C** and **E** show the average of duplicates. In **C**, the background counts in reactions containing the control protein, GFP-binding protein, were subtracted; in **D** and **E**, the control was TIP47 protein. **D**,**F**, and **G** show the combined results of two experiments in duplicate. Numbers at right (**A**) indicate mass in kD for this and all subsequent figures. Reactions contained **D**,**E**,**G**,**H**,**I**, 500 nM total cholesterol; **F**, 5 µM total cholesterol; **B** and **C** were carried out using increasing concentrations of the indicated sterol.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.003](10.7554/eLife.21635.003)10.7554/eLife.21635.004Figure 1---figure supplement 1.Diagram of constructs used.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.004](10.7554/eLife.21635.004)

Cholesterol is poorly soluble, thus binding reactions were carried out in the presence of sub-critical micelle concentration amounts of Nonidet P40 detergent (0.004%) to help solubilize the cholesterol, as worked out by Infante et al. in their studies of cholesterol binding to the N-terminal domain of NPC1 protein ([@bib12]). Under these conditions, most of the cholesterol remains in a mixed micelle of cholesterol and detergent and is still poorly soluble. Thus, the apparent affinity for cholesterol is likely to be tighter than the curves indicate, as the amounts added do not reflect the concentration of free cholesterol that is actually available for binding.

Preliminary experiments showed that ^3^H-cholesterol binding was competed by unlabeled cholesterol, 24-hydroxycholesterol, but not cholesterol sulfate ([Figure 1G](#fig1){ref-type="fig"}). This suggested that binding occurs via the 3β-hydroxyl moiety of the cholesterol molecule, similar to the orientation with which the NPC1 N-terminal domain binds cholesterol ([@bib15]). Consistent with this, LAMP2 also bound ^3^H-25-hydroxycholesterol with similar apparent affinity as cholesterol; binding was competed by excess cold 25-hydroxycholesterol ([Figure 1C](#fig1){ref-type="fig"}), as would be expected for a specific interaction. Only low levels of background binding were detected using GFP-binding protein or TIP47 as controls ([Figure 1D,E](#fig1){ref-type="fig"}). More detailed analysis confirmed that 25-hydroxycholesterol ([Figure 2B](#fig2){ref-type="fig"}) and 7-ketocholesterol ([Figure 2D](#fig2){ref-type="fig"}), but not cholesterol sulfate ([Figure 2A](#fig2){ref-type="fig"}), compete with ^3^H-cholesterol for binding to LAMP2 protein.10.7554/eLife.21635.005Figure 2.Cholesterol binding to LAMP2 is competed by 25-hydroxycholesterol (**B**), cholesterol (**C**), 7-ketocholesterol (**D**) but not cholesterol sulfate (**A**) or epicholesterol (**C**). The structures above indicate the regions of the sterol that differ from cholesterol. In **C**, the background obtained in reactions containing GFP was subtracted. All panels used 50nM ^3^H-cholesterol and the indicated amounts of competitors.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.005](10.7554/eLife.21635.005)

Epicholesterol is a cholesterol epimer that differs only in the chirality of carbon 3 such that the hydroxyl group is in the alpha rather than beta conformation. Importantly, epicholesterol failed to compete for cholesterol binding to LAMP2 protein under conditions where cholesterol competed for binding ([Figure 2C](#fig2){ref-type="fig"}). It was not possible to add higher concentrations of sterol competitors due to solubility issues, but significant inhibition was observed. Together, these data strongly support the conclusion that cholesterol binds LAMP2 via its 3β-hydroxyl moiety.

A slight stimulation of binding was seen in reactions containing low levels of competitor cholesterol sulfate or 25-hydroxycholesterol ([Figure 2A,B](#fig2){ref-type="fig"}); this is presumably due to the higher solubility of these sterols, which will help solubilize ^3^H-cholesterol present in the reaction's mixed micelles, and presumably make it more available for LAMP2 binding (see also ref. [@bib12]). Despite its somewhat higher solubility, 25-hydroxycholesterol did not appear to bind LAMP2 much more tightly than cholesterol, at least as inferred from its ability to compete with cholesterol for binding ([Figure 2B](#fig2){ref-type="fig"}) or to bind directly ([Figure 1C](#fig1){ref-type="fig"}).

The LAMP protein family includes LAMP1, LAMP2, DC-LAMP, BAD-LAMP and Macrosialin ([@bib31]). Each of these proteins contains a related \'LAMP\' domain; LAMP1 and LAMP2 proteins each contain two ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Soluble versions of the individual, membrane distal (\'domain 1\') and membrane proximal (\'domain 2\') LAMP domains of LAMP2 ([Figure 1A](#fig1){ref-type="fig"}) bound cholesterol with different capacity: the N-terminal, domain 1 bound more cholesterol than its membrane proximal, domain 2 counterpart under these conditions ([Figure 1F](#fig1){ref-type="fig"}). It is possible that both are capable of binding cholesterol within the full length molecule, as total domain 1 binding was less than that seen with the full length, secreted LAMP2 construct ([Figure 1F](#fig1){ref-type="fig"}).

To verify that LAMP2 binds cholesterol in cells, soluble LAMP2 protein was expressed and purified from the secretions of HEK293F cells grown in protein-free, FreeStyle 293 Expression Medium that does not contain cholesterol. Under these conditions, any LAMP2-bound sterol must come from intracellular sources. We subjected freshly purified LAMP2 protein to chloroform:methanol extraction and analyzed the extract by thin layer chromatography. As shown in [Figure 3C](#fig3){ref-type="fig"}, the LAMP2 extract contained a molecular species that co-chromatographed with cholesterol but not 24-hydroxy-, 25-hydroxy-, or 26-hydroxycholesterol, lanosterol or 7-beta-hydroxycholesterol. Mass spectrometry of the eluted material ([Figure 3B](#fig3){ref-type="fig"}) confirmed a profile identical with purified cholesterol standard ([Figure 3A](#fig3){ref-type="fig"}) ([Figure 3C](#fig3){ref-type="fig"}). These experiments show that LAMP2 purified from cell secretions carries primarily, bound cholesterol.10.7554/eLife.21635.006Figure 3.Mass spectrometry identification of small molecules released from LAMP2 after chloroform:methanol (2:1) extraction.(**A**) masses from cholesterol standard; (**B**) masses of LAMP2-bound material; (**C**) Copper sulfate/phosphoric acid detection of indicated markers after thin layer chromatography compared with material eluted from soluble LAMP2 (50 µg). Shown are the results of a representative experiment carried out twice.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.006](10.7554/eLife.21635.006)

NPC1 and NPC2 proteins mediate cholesterol export from lysosomes ([@bib15]; [@bib22]). NPC1 has 13 transmembrane domains, and three large, lumenal domains that are important for its function. As mentioned earlier, the NPC1 N-terminal domain binds cholesterol directly ([@bib15]). Because of a possible connection between LAMP protein cholesterol binding and NPC-mediated cholesterol export, we checked for an interaction between these proteins. Membrane anchored, endogenous LAMP2 co-immuno-precipitated with full length NPC1-GFP but not with the control protein, GFP ([Figure 4A](#fig4){ref-type="fig"}) or the lysosomal membrane protein, MCOLN1 ([Figure 4D](#fig4){ref-type="fig"}), upon expression in HEK293T cells. Interestingly, co-immunoprecipitation decreased in cells treated for 24 hr with cyclodextrin to remove cholesterol from lysosomes ([@bib1]; [@bib23]) and the plasma membrane ([Figure 4B,C](#fig4){ref-type="fig"}). These conditions (\~0.1% cyclodextrin) have been shown to be non-toxic (cf. [@bib29]) and did not alter cell growth rate or viability in our hands.10.7554/eLife.21635.007Figure 4.LAMP2 interacts with NPC1 protein.(**A**) Anti-GFP immunoprecipitation from HEK293T cells grown in FBS containing medium expressing GFP or mouse NPC1-GFP. The blot was developed with ECL. Upper panel, anti-GFP immunoblot (100% elution); lower panel, anti-LAMP2 immunoblot to detect endogenous, full length protein (100% elution). **B**,**C**, co-immunoprecipitation of LAMP2 and NPC1-GFP in cells grown in FBS, LPDS (5%) or LPDS + cyclodextrin (1 mM) for 24 hr. Left panels, 1% inputs; right panels, 50% elutions. Error bars represent SEM for two combined experiments carried out in duplicate; P value is from comparison with LPDS by two-tailed Student's t-test. **B** shows duplicate reactions to document reproducibility. **D**, Anti-GFP immunoprecipitation of HEK293T cells grown in FBS expressing GFP-MCOLN1 or mouse NPC1-GFP. GFP-MCOLN1 occurs as a \~90 kD form, a proteolytically processed form, and as higher oligomers ([@bib30]). Left panels, inputs (2%); right panels, total elution carried out in duplicate. GFP proteins are green; LAMP2 is presented in red. Shown is a representative experiment carried out twice in duplicate.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.007](10.7554/eLife.21635.007)

Purified, soluble LAMP2 protein also bound very tightly (and directly) to the N-terminal domain of NPC1 protein ([Figure 5A](#fig5){ref-type="fig"}, red) in the presence (or absence, not shown) of cholesterol (K~D ~= 6 nM), as monitored by microscale thermophoresis using AF647 dye-conjugated NPC1 protein---binding significantly altered the fluorescence of NPC1 protein ([Figure 5C](#fig5){ref-type="fig"}). No interaction was observed for the control glycoprotein, RNase B ([Figure 5E](#fig5){ref-type="fig"}). The smaller, NPC2 protein ([Figure 5B](#fig5){ref-type="fig"}) also bound to LAMP2 (K~D ~= 122 nM), but \~20 fold less tightly that NPC1 N-terminal domain ([Figure 5D](#fig5){ref-type="fig"}); binding was monitored in the presence of cholesterol sulfate which will occupy the binding site of NPC2 but not LAMP2 ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). No binding was seen for NPC2 to the control RNase B protein ([Figure 5F](#fig5){ref-type="fig"}). Thus, LAMP2 binds directly to both NPC1 N-terminal domain and NPC2 proteins. For NPC1, the enhanced binding seen in cells in the presence of cholesterol does not appear to reflect occupancy of NPC1's N-terminal domain, as this variable did not influence LAMP2 binding in solution. However, it is important to note that NPC1 also likely binds cholesterol within its membrane spanning region which may also influence its overall conformation ([@bib19]; [@bib18]).10.7554/eLife.21635.008Figure 5.LAMP2 binds NPC1 and NPC2 proteins.**A**,**B**, Structures of NPC1 ([@bib7]; pdb 3jD8) and NPC2 ([@bib33]; pdb 2 hka) proteins; **C**,**E**, Microscale thermophoresis (**E**) or fluorescence (**C**) obtained with mixtures of soluble, AF647 labeled-NPC1 N-terminal domain or AF647-RNase B with increasing concentrations of soluble LAMP2 in 1 µM cholesterol. **D**,**F**, Microscale thermophoresis of AF647 labeled-NPC2 with increasing concentrations of soluble LAMP2 or RNase B in 1 µM cholesterol sulfate. For **C**--**F**, a representative experiment carried out at least twice is shown.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.008](10.7554/eLife.21635.008)10.7554/eLife.21635.009Figure 5---figure supplement 1.Quantitation of NPC1 (**A**) and LAMP2 (**B**) proteins in HeLa and HEK293T cells.The values at the top of each gel represent the amount of purified protein or total cell extract analyzed, determined by BCA protein assay. The immunoblot was developed using rabbit anti-NPC1 or mouse anti-LAMP2 antibodies followed by detection with IRDye800CW goat anti-mouse or donkey anti-rabbit antibodies. Shown is an example of an experiment carried out in duplicate; subconfluent cultures were analyzed. Purified NPC1 is slightly smaller than that in the extract because it was deglycosylated (see Materials and methods).**DOI:** [http://dx.doi.org/10.7554/eLife.21635.009](10.7554/eLife.21635.009)

LAMP proteins are highly abundant components of the lysosome membrane and may serve as a reservoir for cholesterol extracted from intra-lysosomal membranes by NPC2, prior to cholesterol export from lysosomes by NPC1. \[The term, reservoir, is meant to imply a holding station for cholesterol molecules that have been solubilized from the internal lipid contents of lysosomes by NPC2, and held closer to the limiting membrane, prior to NPC1-mediated export.\]

Are LAMP proteins abundant enough to represent a cholesterol reservoir? We used purified LAMP2 and NPC1 proteins as standards to determine their precise abundance in HeLa and HEK293 cell lysates ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Using the polypeptide molecular weights and cellular protein determinations, we estimate that HeLa cells contain 6.8 × 10^6^ LAMP2 molecules per cell and 3.7 × 10^5^ NPC1 molecules per cell, or 18 fold more LAMP2 than NPC1; HEK293T cells contain 2 × 10^6^ LAMP2 molcules per cell and 5.9 × 10^5^ NPC1 molecules (3.6 × fold more LAMP2).

Baby hamster kidney cells have been estimated to contain an absolute volume of \~37 µm^3^ lysosomes and prelysosomes per cell (3.7 × 10^--14^ l) and a lysosome membrane area of 370 µm^2^ ([@bib9]). Assuming similar values for HeLa cells, this would represent a LAMP2 membrane density of 18,378 or 5676 molecules per µm^2^ in HeLa or 293T cell lysosomes, respectively, consistent with previous reports ([@bib8]). For comparison, tightly packed viral spike glycoproteins occur at a density of 22,000 molecules per µm^2^ ([@bib21]). We assume that LAMP1 will be of similar high density, together with LAMP2, practically lining the interior of the lysosome limiting membrane. In terms of concentrations, 37 femtoliters of lysosome volume would contain 0.3 mM LAMP2-associated cholesterol binding sites in HeLa cell lysosomes (assuming one mole cholesterol bound per more LAMP2). It does not seem unreasonable to consider this as a significant reservoir of cholesterol molecules that may be poised for transfer to NPC1 protein prior to export.

Residues needed for cholesterol binding are needed for LAMP protein function {#s2-1}
----------------------------------------------------------------------------

The structure of an individual LAMP domain from DC-LAMP protein is comprised of a novel, beta-prism fold that appears to contain a hydrophobic pocket ([@bib31]); we used this structure to model the structure of LAMP2 domain 1 ([Figure 6A](#fig6){ref-type="fig"}). Site directed mutagenesis of hydrophobic residues predicted to line the walls of this cavity yielded purified LAMP2 proteins with impaired cholesterol binding activity. Thus, a soluble, LAMP2 domain 1-I^111^A/V^114^A construct yielded a secreted protein ([Figure 6B](#fig6){ref-type="fig"} inset, right lane) that bound significantly less cholesterol than its wild type counterpart ([Figure 6B](#fig6){ref-type="fig"} inset, left lane and panel B). Because these proteins were obtained from cell secretions, they are likely to be properly folded, as they escaped the endoplasmic reticulum's quality control machinery. These experiments show that residues facing the predicted, prism fold pocket are important for cholesterol binding and likely contribute to the cholesterol binding site.10.7554/eLife.21635.010Figure 6.Cholesterol binding to LAMP2 domain 1 is required for its ability to rescue cholesterol export from LAMP-deficient lysosomes.(**A**), predicted structure model of LAMP2 domain 1; residues I111 and V114 are highlighted in red. (**B**) Relative ^3^H-cholesterol binding to soluble LAMP 2 domain 1 or LAMP2 domain 1-I^111^A/V^114^A. Shown is combined data from 5 independent experiments carried out in duplicate in the presence of 50 nM ^3^H-cholesterol. Inset, SDS-PAGE analysis of wild type (left) and domain 1-I^111^A/V^114^A (right) proteins analyzed. P value was determined by two-tailed Student's t-test. (**C**) flow cytometry analysis of mean fluorescence of GFP rescue constructs in lentivirus-tranduced cells (\>20,000 cells analyzed). (**D**) Cholesteryl oleate synthesis in MEF cells lacking LAMP1 and LAMP2 after rescue with either full length, membrane anchored LAMP2, membrane anchored LAMP2 domain 1, or membrane anchored LAMP2 domain 1-I^111^A/V^114^A. C-terminally GFP-tagged, rescue proteins were stably expressed using lentivirus transduction; shown is the combined result of 2 independent experiments, normalized for the amount of mature protein in each sample ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) relative to the amount of rescue seen with full length LAMP2 protein. P-values are in relation to full length for domain 1, or to domain 1 for the mutant protein, and were determined by one way ANOVA. E, confocal light microscopic analysis of GFP rescue construct localization (green) and endogenous LAMP1 protein (red) in transiently transfected HeLa cells; bars represent 20 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.010](10.7554/eLife.21635.010)10.7554/eLife.21635.011Figure 6---figure supplement 1.Immunoblot analysis of LAMP2 constructs from lentivirus transduced LAMP1/LAMP2-knock out MEF cells.(**A**) total cell extract from cells expressing membrane anchored, GFP-LAMP2 domain 1 or GFP-LAMP2 domain 1-I^111^A/V^114^A; (**B**) migration of the constructs indicated, before or after 4 hr cycloheximide treatment (50 µg/ml). Panel **A** was developed as in [Figure 4B](#fig4){ref-type="fig"}; panel **B** was developed as in [Figure 4A](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.21635.011](10.7554/eLife.21635.011)

Finally, to verify the importance of cholesterol binding to LAMP2 protein as part of its physiological role, we tested the ability of wild type and mutant LAMP2 constructs to rescue the cholesterol accumulation seen in lysosomes from mouse embryonic fibroblasts missing LAMP1 and LAMP2 proteins ([@bib5]; [@bib25]). The ability of lysosomes to export cholesterol can be monitored by feeding cells cholesterol in the form of LDL, and using conversion of ^14^C-oleic acid to cholesteryl oleate that takes place after endocytosed cholesterol is transported to the endoplasmic reticulum ([@bib6]). Previous work showed that LAMP1/2 knockout MEF cells were impaired in cholesterol export using this assay ([@bib25]).

We used lentivirus transduction to test the ability of full length LAMP2, a membrane anchored LAMP2 domain 1 (LAMP2-GFP Δ194--368; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), or a membrane anchored LAMP2 domain 1-I^111^A/V^114^A to rescue the ability of LAMP1/LAMP2 knockout MEF cells to export LDL-derived cholesterol from lysosomes. For these experiments, we used LAMP constructs containing a single LAMP domain, as full length LAMP2 constructs with mutations in both LAMP domains failed to fold properly or be transported efficiently to lysosomes.

It was important to first verify the precise amounts of each construct in lysosomes, to evaluate any functional rescue findings. Flow cytometry analysis showed that the rescue constructs were expressed at comparable levels in each stably expressing cell population ([Figure 6C](#fig6){ref-type="fig"}). Light microscopy confirmed that the constructs were capable of proper lysosome localization, as determined by their colocalization with endogenous LAMP1 protein ([Figure 6E](#fig6){ref-type="fig"}) in HeLa cells. (Similar staining was observed in LAMP knockout MEF cells that lack LAMP protein markers).

To fully confirm the folding of these artificial constructs, we analyzed their glycosylation status and stability after addition of cycloheximide to inhibit new protein synthesis ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Full length GFP-LAMP2 protein migrated at \~140 kD and its abundance was not altered after 4 hr cycloheximide treatment, consistent with its long half life in cultured cells (panel B). Similarly, the GFP-domain 1 construct was stable under these conditions and migrated at \~90 kD (panels A,B). In contrast, the I^111^A/V^114^A mutant domain I protein displayed two distinct bands; the upper band was stable, while the lower band likely corresponded to an ER form that was largely degraded after 4 hr in cycloheximide (panels A,B). From this we conclude that cells expressing membrane anchored LAMP2 domain 1 I^111^A/V^114^A are less efficient at folding the protein but some folded protein makes it to lysosomes, where it is stable. This difference was accounted for in subsequent functional rescue experiments ([Figure 6D](#fig6){ref-type="fig"}).

[Figure 6D](#fig6){ref-type="fig"} shows that as expected, full length, wild type LAMP2 rescued cholesterol export in LAMP1/2-deficient MEF cells; membrane anchored LAMP2 domain 1 showed a level of rescue consistent with its lower capacity for cholesterol binding (cf. [Figure 1F](#fig1){ref-type="fig"}). Importantly, membrane anchored, LAMP2 domain 1 I^111^A/V^114^A failed to rescue cholesterol export from lysosomes ([Figure 6D](#fig6){ref-type="fig"}), consistent with its inability to bind cholesterol; shown are the data corrected for the amount of mature proteins present in lysosomes in these cells. LAMP2 constructs mutated in both cholesterol-binding sites could not be tested, as they were only poorly delivered to lysosomes.

These experiments demonstrate a direct role for LAMP2 in cholesterol export from lysosomes, and confirm that LAMP2's ability to bind cholesterol correlates with its ability to support cholesterol export from LAMP-deficient MEF cells. In addition, LAMP proteins bind tightly to NPC proteins in vitro and in cells, and appear to facilitate cholesterol export from lysosomes.

LAMP proteins are the most highly abundant membrane glycoproteins of the lysosome, and their lumenally oriented cholesterol binding sites represent a significant binding site for this important sterol. We measured \~7 × 10^6^ molcules per HeLa cell, representing 0.3 mM binding sites in lysosomes. A recent cellular mass spectrometry analysis ([@bib13]) estimated LAMP proteins to be present at 260,000 copies and NPC1 at 29,193 copies per HeLa cell. While the relative abundance of these proteins matches the values we report here, their total level was 25 fold lower in that study. It is possible that these transmembrane glycoproteins were under-represented in due to their unusual protease resistance as proteins of the lysosome membrane, differences in cell confluency and/or differences in HeLa cell lines employed.

Lysosomes have recently been shown to sense and signal amino acid availability to influence lysosome biogenesis in relation to cellular need ([@bib27]), and LAMP oligomerization has been reported to correlate with chaperone mediated autophagy ([@bib2]). Cholesterol levels may influence LAMP protein conformation or interaction with other partners to signal the availability of endocytosed cholesterol to influence autophagy and cellular metabolism. The ten fold higher abundance of LAMP proteins compared with NPC1 protein in HeLa cells suggests that LAMP proteins may do more than just facilitate NPC1 function in cholesterol export. Future experiments will be needed to fully understand the roles played by these highly abundant lysosomal membrane glycoproteins.

We have shown that LAMP2 binds tightly to the N-terminal domain of NPC1 and also binds cholesterol with the same orientation as that domain. LAMP2 also aids in cholesterol export from lysosomes. How might LAMP2's cholesterol binding site contribute to cholesterol export? Current models suggest that the soluble NPC2 protein binds cholesterol from the internal membranes of lysosomes and delivers it to NPC1 at the limiting membrane of this compartment ([@bib15]). One possibility is that NPC2 can deliver cholesterol to both NPC1 and to LAMP2, which is more abundant. This would help drive the cholesterol export process by moving cholesterol from the accumulated, lumenal lipid stores to the lysosome's limiting membrane. Because LAMP2 and NPC1 N-terminal domains bind cholesterol in the same orientation, it makes sense that NPC2 (which binds in opposite orientation, \[[@bib33]\]) could transfer the cholesterol between these two proteins. The recent crystal structure of NPC2 bound to the middle, lumenal domain of NPC1 ([@bib18]) supports a direct handoff between NPC1 and NPC2 ([@bib15]). In future work, it will be important to elucidate precisely how LAMP2 interacts with both NPC2 and NPC1 to facilitate cholesterol export from lysosomes and how cholesterol binding contributes to LAMP2's other cellular roles.

Materials and methods {#s3}
=====================

Cholesterol, epicholesterol and sodium cholesteryl sulfate were from Sigma (St. Louis, MO); 24-hydroxycholesterol (24-HC) was a gift from Rajat Rohatgi (Stanford University, Stanford, CA); 25-hydroxycholesterol and 7-ketocholesterol were from Steraloids (Newport, RI) or Avanti Polar Lipids (Alabaster, AL); \[1,2-^3^H\]cholesterol (50 Ci/mmol) and 25-\[26,27-^3^H\] hydroxycholesterol were from American Radiolabeled Chemicals (St. Louis, MO). Ni-NTA agarose was from Qiagen (Valencia, CA); freestyle 293 expression medium and Dulbecco's modified Eagle's medium (DMEM) was from Life Technologies (Carlsbad, CA); lipoprotein deficient serum was from KALEN Biomedical (Montgomery Village, Maryland). Pierce Protein Concentrators PES were from Thermo Fisher Scientific (Grand Island, NY); PD-10 desalting columns and Q-Sepharose were from GE Healthcare Life Sciences (Pittsburgh, PA); pFastBac NPC1-N-terminal domain plasmid, LAMP1-mGFP and MCOLN1-pEGFP C3 were from Addgene (Cambridge, MA); pGEM-LAMP2 was from Sino Biological Inc; mouse anti-human LAMP1 and LAMP2 antibody culture supernatants were from Developmental Studies Hybridoma Bank (University of Iowa, Iowa city, IA). Rabbit monoclonal anti-NPC1 was from AbCam (Cambridge, MA); Chicken anti-GFP antibody was from Aves Labs (Tigard, Oregon); IRDye 800CW donkey anti-chicken and IRDye 680RD donkey anti-mouse antibodies were from LI-COR, Inc. (Lincoln, NE); anti-chicken-HRP conjugate was from Promega (Sunnyvale, CA); goat anti-mouse-HRP conjugate was from BioRad (Hercules, CA); ECL Western Blotting Substrate was from Thermo Scientific (Rockford, IL).

Buffers {#s3-1}
-------

Buffer A: 50 mM ammonium acetate, pH4.5, 150 mM NaCl, 0.004% NP-40; buffer B: 50 mM MES, pH5.5, 150 mM NaCl, 0.004% NP40; buffer C: 50 mM MES, pH6.5, 150 mM NaCl, 0.004% NP-40; buffer D: 50 mM HEPES, pH7.5, 150 mM NaCl, 0.004% NP-40; buffer E: 25 mM Tris, pH7.4, 150 mM NaCl; RIPA buffer: 50 mM Tris, pH7.4, 150 mM NaCl, 1% NP-40, 0.2% deoxycholic acid, 0.1% SDS.

Plasmids {#s3-2}
--------

cDNAs encoding full length, soluble human LAMP1(1--382), human LAMP2 (1--375) and domain 1 of human LAMP2 (1--231) were PCR amplified from LAMP1-mGFP and pGEM-LAMP2 respectively. The PCR products were inserted into pEGFP-N3 vector. The constructs were assembled to have an unstructured GSTGSTGSTGA linker at the C terminus, followed by a His~10~ tag and a FLAG tag. For LAMP2, another His~10~ tag was added downstream of the FLAG tag for improved purification. LAMP2 domain 2 was prepared by deleting residues 39--219 from the full length, soluble domain construct. FUGENE6 was used for transient transfection of HeLa cells. Membrane anchored rescue constructs were stably expressed in LAMP1/2 deficient MEF cells by lentivirus transduction and were comprised of full length LAMP2 bearing a C-terminal GFP (LAMP2-GFP), or LAMP2-GFP Δ194--368 (encoding membrane anchored domain 1) or the latter construct carrying point mutations.

Cell lines {#s3-3}
----------

Authenticated HEK293F, HEK293T, and HeLa cells were from ATCC and used at low passage; Sf9 cells were purchased from Thermo Fisher Scientific (Waltham, MA); Mouse embryonic fibroblasts from LAMP1/LAMP2 double knockout mice ([@bib2]; [@bib5]) were the generous gift of Dr. Paul Saftig (Christian-Albrechts-Universität Kiel, Germany). Mycoplasma contamination was monitored by DAPI staining.

Cell culture {#s3-4}
------------

All cells were cultured at 37°C and under 5% CO~2~ in Dulbecco's modified Eagle's medium supplemented with 7.5% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin, unless indicated. HEK293F suspension cells were **c**ultured at 37°C under 5% CO2 in Freestyle 293 medium. In some experiments, cells were cultured in lipoprotein deficient serum (5%).

Protein purification {#s3-5}
--------------------

pFastBac NPC1-N-terminal domain plasmid was used to make virus for infection of Sf9 insect cells. 72 hr after infection, Sf9 cultures were spun down and ammonium sulfate added to achieve 60% saturation. The resulting precipitate was re-suspended buffer E and incubated with Ni-NTA resin overnight at 4°C. After washing with buffer E with 25 mM imidazole, the protein was eluted with buffer E plus 250 mM imidazole, and further purified using Q-Sepharose.

HEK293F cells were transfected using 293fection according to the manufacturer. After 72 hr, supernatants were collected after spinning 3000 rpm for 5 min. To purify proteins for \[^3^H\] cholesterol binding, supernatants were subjected to 90% ammonium sulfate precipitation. After spinning at 13,000 rpm for 30 min, pellets were re-suspended in buffer E plus 25 mM imidazole and incubated with Ni-NTA resin overnight at 4°C, followed by washing with the same buffer. Bound proteins were eluted with buffer E plus 250 mM imidazole. Proteins were concentrated and buffer exchanged into buffer C with Pierce Protein Concentrators PES (10 kD cut-off). Proteins were either used immediately or stored at −80°C after snap freezing in liquid nitrogen. For cholesterol extraction and thin layer chromatography, supernatants were adjusted to pH 7.4 and incubated with Ni-NTA resin overnight at 4°C; after washing with buffer E plus 25 mM imidazole, proteins were eluted with buffer E plus 250 mM imidazole. Proteins were desalted into PBS using a PD-10 column.

^3^H-cholesterol binding {#s3-6}
------------------------

Each reaction was carried out in a final volume of 80--100 µl of buffer A, B, C or D containing 0.1--1 µg purified His-tagged protein, 1µg BSA and 10--400 nM ^3^H-cholesterol diluted with 0.1--50 µM cholesterol. For competition assays, reactions were in 80 µl buffer C (50 mM MES, 150 mM NaCl, 0.004% NP-40, pH6.5) with 0.1 µg full length soluble LAMP2 protein and 50 nM ^3^H-cholesterol, competition was started by adding vehicle (ethanol) or different concentrations of competitors as indicated. After incubation overnight at 4°C, the mixture was loaded onto a column packed with 30 µl Ni-NTA agarose beads. After incubation for 10 min, each column was washed with 5 ml of buffer C plus 10 mM imidazole. The protein-bound ^3^H-cholesterol was eluted with 250 mM imidazole-containing buffer C and quantified by scintillation counting.

Mass spectrometry {#s3-7}
-----------------

Samples were analyzed by LC/MS on an Agilent 1260 HPLC and Bruker microTOF-Q II mass spectrometer. Full scan mass and product ion spectra were acquired in positive ion mode, using a Phenomenex Kinetex C18 2.6u 2.1 × 100 mm column, and an initial condition of 30%, 0.1% formic acid in water/70% methanol.

Thin layer chromatography {#s3-8}
-------------------------

Full length soluble LAMP2, and domains 1 and 2 of LAMP2 were purified as described above. Extraction was performed by adding 3 sample volumes of chloroform/methanol (2:1, v/v) to the samples. After repeating once more, extracts were pooled and dried under nitrogen. The extracts were re-dissolved in 50--100µl chloroform/methanol (2:1, v/v). Samples were spotted onto a Silica gel plate. The plate was developed with isopropanol until the front reached 1cm above the loading position; after drying under airflow, the plate was further developed using 2% methanol in chloroform until the front reached the top of the plate. The plate was sprayed with 10% CuSO~4~ in 4% or 8% phosphoric acid and heated at 180°C to visualize the samples.

Co-immunoprecipitation {#s3-9}
----------------------

HEK293T cells expressing pEGFP-N1, pEGFP-N1-mNPC1 or pEGFP-C3-MCOLN1 were harvested 24--48 hr post-transfection and lysed in lysis buffer (50 mM MES, pH 5.5, 150 mM NaCl and 0.1% digitonin) supplemented with protease inhibitors. After 30 min on ice, lysates were spun at 15,000 g for 15 min, and protein concentrations of the supernatants were measured. Equal amounts of extract protein were incubated with GFP-binding protein--conjugated agarose for 2 hr at 4°C. Immobilized proteins were washed 4 times with 1ml lysis buffer, eluted with 2× SDS loading buffer, and subjected to BioRad Mini-PROTEIN TGX 4--20% gradient gels. After transfer to nitrocellulose membrane and antibody incubation, blots were detected with ECL western blotting detection substrate or visualized using LI-COR Odyssey Imaging System.

Microscale thermophoresis (MST) {#s3-10}
-------------------------------

MST experiments were performed on a Monolith NT.115Pico instrument (Nanotemper Technologies). Briefly, His~6~-NPC1 N-terminal domain, RNase B or NPC2 were labeled using the RED-NHS (Amine Reactive) Protein Labeling Kit (Nanotemper Technologies). A constant concentration of 6 nM labeled protein was mixed with binding partnerswith a final buffer condition of 50 mM MES, pH 5.5, containing 150 mM NaCl, 0.004% NP-40. Premium coated capillaries contained 16 sequential, 2 fold serial dilutions. Analysis was at 40% laser power for 30 s, followed by 5 s cooling. Data were normalized to fraction of bound (0 = unbound, 1 = bound). The dissociation constant *K~D~* was obtained by plotting the normalized fluorescence F~norm~ against the logarithm of the different concentrations of the dilution series according to the law of mass action.

Quantitation of intracellular LAMP2 and NPC1 protein {#s3-11}
----------------------------------------------------

HeLa and HEK293T cells were grown to sub-confluence in DMEM supplemented with 7.5% FBS. One 10cm dish of cells was washed 3 times with cold PBS, then lysed with 500µl RIPA buffer with protease inhibitor cocktail (Sigma). After 30 min on ice, the lysate was centrifuged at 13,000 rpm for 15 min at 4°C. The resulting supernatant was transferred to a new tube and protein was measured by BCA assay. Lysates were resolved by SDS-PAGE, using different amounts of purified human LAMP2 or NPC1 protein as standards. After transfer to nitrocellulose, the blot was probed with anti-human LAMP2 or NPC1 antibody followed by IRDye 800CW labeled anti mouse (for LAMP2) or rabbit (for NPC1) secondary antibody, and visualized using a LI-COR Odyssey Imaging System and analyzed using ImageJ software. Calculations were based on molecular weights of 45,874 for LAMP2 and 142167 for NPC1 polypeptide chains, and neglected glycan contribution, which is not measured in the protein assay employed. Purified, full length NPC1 protein was the gift of Dr. Xiaochun Li (Rockefeller University) and was N-glycanase treated.

Other methods {#s3-12}
-------------

Confocal immunofluorescence microscopy was carried out as described ([@bib16]). Cells grown on coverslips were fixed with 3.7% (vol/vol) paraformaldehyde for 15 min at room temperature. LAMP1 staining was performed with sequential incubation of mouse anti-LAMP1 culture supernate and Alexa Fluor 594 goat anti-mouse antibody (1:1,000, Invitrogen), each for 1 hr at room temperature. Coverslips were mounted using Mowiol and imaged using a Leica SP2 confocal microscope and Leica software with a 60 × 1.4 N.A. Plan Apochromat oil immersion lens and a charge-coupled device camera (CoolSNAP HQ, Photometrics). Flow cytometry was carried out on a FACScan Analyzer on gently trypsinized cells fixed as described above ([@bib16]). Structures were presented in drawings created using Chimera software ([@bib20]).

Cholesterol ester formation {#s3-13}
---------------------------

LAMP1/LAMP2-deficient MEF cells were cultured in DMEM medium with 5% (vol/vol) LPDS for two days and assayed ([@bib6]; [@bib16]) with minor modification. After 48 hr, 100 µg/mL LDL, 50 µM lovastatin, and 50 µM sodium mevalonate were added for 5 hr. Cells were pulse labeled for 4 hr with 0.1 mM sodium \[1-^14^C\]oleate (American Radiolabeled Chemicals)--albumin complex. Cells were washed two times with 2 mL 50 mM Tris, 150 mM NaCl, 2 mg/mL BSA, pH 7.4, followed by 2 mL 50 mM Tris, 150 mM NaCl, pH 7.4. Cells were extracted and rinsed with hexane-isopropanol (3:2), pooled, and evaporated. After resuspending each sample in 60 µl hexane, 4 µL of lipid standard containing 8 µg/mL triolein, 8 µg/mL oleic acid, and 8 µg/mL cholesteryl oleate was added. Samples were spotted onto a silica gel 60 plastic backed, thin layer chromatogram and developed in hexane. Cholesteryl oleate was identified with iodine vapor, scraped from chromatograms, and radioactivity determined by scintillation counting in 10 mL Biosafe II.

Statistical analysis {#s3-14}
--------------------

Minimum sample sizes were determined assuming 5% standard error and \>95% confidence level. p values were determined using Graphpad Prism software and are indicated in all figures according to convention: \*p≤0.05; \*\*p≤0.01; \*\*\*p≤0.001; \*\*\*\*p≤0.0001. Error bars represent standard error of the mean.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export\" for consideration by *eLife*. Your article has been favorably evaluated by Vivek Malhotra (Senior Editor) and three reviewers, one of whom, Chris G Burd (Reviewer \#1), is a member of our Board of Reviewing Editors, and another one is Frederick Maxfield (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Li and Pfeffer have investigated cholesterol binding by lysosomal LAMP proteins. They report that soluble, secreted fragments of the lumenal portions of LAMP1 and LAMP2 exhibit specific binding of cholesterol. Specificity of binding is suggested by saturation binding kinetics, competition experiments, and point mutagenesis. Full-length, endogenous LAMP2 is shown to co-immunoprecipitate with GFP-tagged NPC1 and NPC2 expressed by transfection and this association is diminished by treatment of cells to reduce late endosome cholesterol. Co-IP of LAMP2 and NPC1 is correlated with oligomeric state of LAMP1, where cholesterol promotes dissociation of LAMP1 oligomers and results in a decrease in the amount of LAMP2-NPC1 complex. Finally, the authors show that mutations in the lumenal domain of LAMP2 that ablate cholesterol binding do not support NPC1-mediated efflux of cholesterol from the lysosome.

Essential revisions:

The reviewers agreed that your findings that LAMP proteins bind to cholesterol and promote NPC1,2-mediated cholesterol export from the lysosome are potentially impactful for the field. However, four major concerns, listed below, were raised with several aspects of the work that must be definitively addressed in order to further advance the paper at *eLife*. While the reviewers indicated their willingness to recommend consideration of a revised manuscript by *eLife*, given the fundamental nature of several concerns, they also recommended that a revised manuscript should be evaluated by each reviewer.

1\) The affinities and specificities of cholesterol binding to LAMP proteins is not adequately demonstrated.

It is concluded that 3H-cholesterol binds to LAMP2 with an affinity of Km \~ 5 µM. Given that the solubility of cholesterol in water is less than 100 nM, this result raises several critical questions. First, it is possible that a more soluble contaminant (e.g., an oxysterol) is responsible for the competition. Another possibility is that the cholesterol is in some type of micelle with the NP40 detergent. In either case, it is hard to know how to evaluate the concentration of cholesterol in these experiments. The authors need to elucidate the form of cholesterol that is bound by LAMP proteins.

The reviewers noted that the one-point competition experiments in [Figure 1G](#fig1){ref-type="fig"} are suggestive of specificity, but they agreed that it is essential to examine other structurally similar sterols (e.g., lanosterol), instead of cholesterol sulfate, which is more soluble than cholesterol. In addition, the competition data needs to show concentration curves of unlabeled competitor sterols.

2\) The lipid components of the membranes from which LAMP2 is purified and bound lipids identified ([Figure 2](#fig2){ref-type="fig"}) must be determined. It is key to evaluate the co-purification data in light of the abundances of cholesterol versus other abundant lipids in lysosomal membranes such as phospholipids and sphingolipids. 7-β-hydroxy cholesterol and 26-hydroxy-cholesterol are present at trace levels in cells when compared to cholesterol, and are not appropriate controls for this experiment.

3\) The conclusions that NPC1 and LAMPs bind each other and that this is regulated by cholesterol-dependent changes in oligomeric state of LAMP require additional support. Regarding the LAMP2-NPC1 binding experiment shown in [Figure 3C](#fig3){ref-type="fig"}, data should be shown for reactions carried out in the absence of cholesterol. It was noted that the primary data showing cholesterol dependence of binding shown in [Figure 3B](#fig3){ref-type="fig"} was not shown and further, that the approach does not afford sufficient control of cholesterol level to firmly support the authors\' conclusion that LAMP2 and NPC1 do not bind in the absence of cholesterol.

4\) The reviewers had difficulty envisioning the role of LAMP proteins in NPC1,2-mediated cholesterol export from the lysosome as you suggest in the manuscript, and this requires serious consideration in the presentation of the proposed model. Specifically, previous work has suggested that NPC2 and NPC1-NTD bind cholesterol with opposite orientation of the hydroxyl, which would allow cholesterol to slide from one pocket to the other. If LAMPs and NPC1-NTD have the same orientation, this will not work; cholesterol would remain bound to LAMP. Related to this point, one reviewer raised the point that LAMPs seem better suited to be cholesterol sensors rather than \"reservoirs\". Compared to the capacity of the lysosome membrane to harbor cholesterol, are there really sufficient numbers of LAMP proteins per lysosome to constitute a \"reservoir?\"

\[Editors\' note: a revised version of this study was rejected after a second round of peer review, but the authors resubmitted for consideration, and the new manuscript was deemed suitable for publication.\]

Thank you for submitting your work entitled \"Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export\" for consideration by *eLife*. Your article has been favorably evaluated by Vivek Malhotra (Senior Editor) and three reviewers, one of whom, Chris G Burd (Reviewer \#1), is a member of our Board of Reviewing Editors, and another one is Frederick Maxfield (Reviewer \#2).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

Overall, the reviewers found this to be an interesting and potentially important study. However, lingering concerns with several fundamental aspects of the study drove the editor\'s decision. Regarding cholesterol binding by LAMP proteins, the reviewers acknowledged the encouraging data that supports this conclusion, but there remains concern with the methodology, including a suggestion for more rigorous controls for non-specific binding. There was agreement amongst the reviewers that a well-supported and fundamental advance regarding the mechanism of cholesterol export has yet to emerge the experiments that probed interactions between LAMP2 and NPC1 (and possibly NPC2), and also the data presented regarding LAMP2 oligomerization.

*Reviewer \#1:*

The authors have responded to each of the four major issues that were raised during the initial review. Each is addressed below.

\"1) The affinities and specificities of cholesterol binding to LAMP proteins is not adequately demonstrated.\"

New competition binding data ([Figure 2](#fig2){ref-type="fig"}) over a 50-fold concentration range (I think -- see below) show that 25-hydroxycholesterol and 7-ketocholesterol, but not cholesterol sulfate or lanosterol, compete with cholesterol for binding to secreted LAMP2 lumenal domain. The data, particularly for lanosterol, support the authors\' conclusion that the 3β position of cholesterol is recognized by LAMP2.

The methods section needs to be updated. It is stated that competition experiments were done only in the presence of 30 μM unlabeled sterol.

\"2) The lipid components of the membranes from which LAMP2 is purified and bound lipids identified ([Figure 2](#fig2){ref-type="fig"}) must be determined.\"

The authors point out that the material that was analyzed was secreted LAMP2, not material extracted from a membrane. I\'m sorry -- my mistake for not appreciating this previously. This, and the additional mass spectra analyses provide further support that cholesterol is specifically recognized by LAMP2.

\"3) The conclusions that NPC1 and LAMPs bind each other and that this is regulated by cholesterol-dependent changes in oligomeric state of LAMP require additional support.\"

These concerns have been addressed with additional experiments.

The evidence presented in support of the conclusion that LAMP (LAMP1, in this case) dimerizes as a result of cholesterol depletion is an increase in the abundance of a high molecular weight species, consistent with a dimer, on a gel by anti-LAMP1 blot of cell extracts. Dimerization is one possibility. It could also be explained by an association with another protein, a conformational change, etc. While the magnitude in the increase in the putative LAMP1 dimer is statistically significant, it is a small proportion of the total LAMP1.

The IP in [Figure 4A](#fig4){ref-type="fig"} controls for co-IP of LAMP2 and NPC1-GFP, two integral membrane proteins, using just soluble GFP. A more appropriate and convincing control for specificity would be an unrelated GFP-tagged integral membrane protein.

The authors now report that binding of purified LAMP2 and NPC1 N-term domain proteins is not affected by the presence or absence of cholesterol, though co-IP of the full length proteins from cells is diminished when cells are incubated with cyclodextrin. The authors also report that LAMP proteins are present in approx. 10-fold excess of NPC1, and that binding between the luminal domains of LAMP2 and NPC1 in vitro are not affected by cholesterol occupancy. Given the 5 nM KD affinity of the interaction measured in vitro, it seems most likely to me that they would be associated constitutively (meaning, in the presence of absence of cholesterol) in the lysosome membrane.

Overall, with regards to the mechanism, it\'s unclear to me what the data is telling us. Regardless of the mechanism, the data do support, in my opinion, the conclusion that LAMP2 plays a role in cholesterol efflux from the lysosome and that this is correlated with cholesterol binding to LAMP2.

\"4) The reviewers had difficulty envisioning the role of LAMP proteins in NPC1,2-mediated cholesterol export from the lysosome as you suggest in the manuscript, and this requires serious consideration in the presentation of the proposed model.\"

With the clarification of the manner in which the authors use \"reservoir,\" along with the determination of LAMP protein abundance, I agree that it is plausible that LAMP proteins provide a physiologically relevant \"reservoir\" of cholesterol to be a component of the NPC1- and NPC2-mediated lysosomal cholesterol efflux pathway.

*Reviewer \#2:*

In general the authors have addressed my major concerns. However, I still have some questions and concerns that need to be addressed.

1\) I don\'t understand the comment in the fourth paragraph of the Results and Discussion section. I don\'t see how having 25-OH cholesterol will improve the solubility of cholesterol and increase its binding.

2\) The treatment of wild type cells with cyclodextrin is confusing to me. Does it actually reduce cholesterol in the late endosomes/lysosomes? Without showing this, the effect on LAMP1 is hard to interpret. I am also concerned about the health of cells in LPDS and 1 mM CD for 24 hours.

3\) In the eighth paragraph of the Results and Discussion section. This explanation does not make sense to me. Only a small fraction of the LAMP is dimerized. There is still abundant monomer, which could interact with NPC1. I would recommend deleting the CD treatment and the LAMP dimerization. It is not key to the paper.

*Reviewer \#3:*

In this revision, the authors have attempted to address the concerns raised with the cholesterol binding data and with their claims of cholesterol-regulated behavior of LAMP proteins and interaction with NPC proteins. Unfortunately, almost all of my concerns remain.

Specific points:

My previous review: "The assay showing direct binding of 3H-cholesterol to LAMP2 has no specificity controls ([Figure 1B](#fig1){ref-type="fig"}). Since 3H-cholesterol binding to LAMP2 shows weak affinity (Km \~ 5 µM), it is imperative to show that some other hydrophobic 3H-ligand does not bind to LAMP2 at these high concentrations where hydrophobic ligands often precipitate. The one-point competition experiments in [Figure 1G](#fig1){ref-type="fig"} are suggestive of specificity, but the authors should try lanosterol (or some other structurally similar sterol) as a negative control, instead of cholesterol sulfate which is more soluble than cholesterol. The competition data also needs to show concentration curves of unlabeled competitor sterols. The authors\' claim of similar binding of cholesterol to LAMP2 and NPC1-NTD is misleading since they compare saturation stoichiometries, not the more relevant affinity parameters. To rule out non-specific binding of insoluble cholesterol to LAMP2, careful controls are needed".

The authors now say that they carried out binding reactions in the presence of sub-cmc concentrations of detergent. This sounds good, but the Methods section does not say anything about this. The only place the detergent is mentioned is in a new paragraph in the Results, but no details are given. All the binding data in [Figure 1](#fig1){ref-type="fig"} is identical to what was in the first submission. So, did the authors redo these with sub-cmc detergent and get the same results? In any case, even if the authors had merely not reported their experimental procedures accurately in the original submission, none of the concerns previously raised have been addressed.

A\) The key data is in [Figure 1B](#fig1){ref-type="fig"} which shows a saturation binding curve of 3H-cholesterol to LAMP2 that shows very weak affinity -- Km = 5-10 µM. This solitary curve is hard to interpret without carrying out the same dose curve in the presence of excess unlabeled cholesterol, which would indicate the background non-specific binding. Also, they need to show that some other 3H-sterol ligand does not bind LAMP2 in the same experiment. They claim later that 25-HC competes and lanosterol does not compete. Both of these sterols are available commercially in tritiated form. 3H-lanosterol would have been a great control for specificity.

B\) The next key pieces of data are in 1G and 1H. Again, these panels are identical to the original submission, and once again it is not clear how much 3H-cholesterol was used. From extrapolation using 1B, it looks like around 5 µM, but details like these are critical and need to be indicated. In any case, 1H shows competition by unlabeled cholesterol, but there is no negative control with a non-competitor like cholesterol sulfate. The authors now add competition curves by other unlabeled sterols in [Figure 2](#fig2){ref-type="fig"}. Unfortunately, these cannot be judged because once again it is not clear how much 3H-cholesterol was used and the raw binding values that were normalized to 1.0 are not indicated. The authors should use cpm units so that we can compare with [Figure 1](#fig1){ref-type="fig"} data. Also, every competition curve in [Figure 2](#fig2){ref-type="fig"} requires a positive control and a negative control in the same experiment to be able to judge anything. They show competition curve for unlabeled cholesterol out to 15 µM in [Figure 1H](#fig1){ref-type="fig"}, but all the other competition curves are upto 50 µM -- what happens with unlabeled cholesterol at these concentrations. Based on the cholesterol data, the competitors should be judged by their ability to compete at 15 µM. Only 7-ketocholesterol seems to be a strong competitor. Also, why did they not do competition curves for 24-hydroxycholesterol, which according to [Figure 1G](#fig1){ref-type="fig"} was the strongest competitor? How about epicholesterol, where the 3-hydroxyl region is modified in a manner more subtle than cholesterol sulfate. The claim that the 3β-hydroxyl group of cholesterol enters the binding pocket cannot be made from these data.

C\) The mass spec data showing cholesterol is present in purifications could be due to the high concentrations of cholesterol, but not their control sterols, in the serum-rich media into which the proteins were secreted. Again, no details of the growth conditions are given so that we can judge these results.

My previous review: "The claim that LAMP proteins oligomerize when cholesterol is limiting and associate with NPC1 when cholesterol is available is not supported by the data of [Figure 3](#fig3){ref-type="fig"}. The association of NPC1 with LAMP2 is shown by IP in [Figure 3A](#fig3){ref-type="fig"}, but no cholesterol dependence for this interaction is shown (the raw data for the bar graph in 3B is not shown). Instead, the interaction of NPC1 with LAMP2 in the presence of cholesterol is shown by a different method in [Figure 3C](#fig3){ref-type="fig"}, but this experiment does not show what happens in the absence of cholesterol! [Figure 3G](#fig3){ref-type="fig"} shows a partial effect of cholesterol on LAMP1 dimerization, but not on LAMP2 oligomers. The key lane on the gel in [Figure 3G](#fig3){ref-type="fig"} is shown in isolation without any controls, so the significance of higher density of dimer is not clear. The quantification needs to be done on a gel from a single experiment with LAMP2."

The authors had previously claimed cholesterol dependency of NPC1-LAMP2 interaction, but had not shown the data in a single experiment. They now say that there is no cholesterol dependence, but again do not show the data!

The IP data showing interaction between LAMP2 and NPC1-GFP (a membrane protein) uses GFP (soluble protein) as a control. They would need to use another lysosomal membrane protein as a control to rule in specificity. Again, they claim that LAMP1 dimerizes using a gel where the key lane is shown in isolation without any controls ([Figure 4D, E](#fig4){ref-type="fig"}), so the significance of the slightly higher density of the dimer is not clear. The quantification needs to be done on a gel from a single experiment with LAMP1.

Eskelinen et al., 2004 and Schneede et al., 2011 have already highlighted the roles of Lamp2 in cholesterol transport, the key advance in this study is to attempt to show a direct interaction between cholesterol and LAMP proteins and to get at the mechanism. Neither of these points are supported by their data, and as such I do not think this paper makes a significant contribution to this problem.

10.7554/eLife.21635.013

Author response

*Essential revisions:*

*The reviewers agreed that your findings that LAMP proteins bind to cholesterol and promote NPC1,2-mediated cholesterol export from the lysosome are potentially impactful for the field. However, four major concerns, listed below, were raised with several aspects of the work that must be definitively addressed in order to further advance the paper at eLife. While the reviewers indicated their willingness to recommend consideration of a revised manuscript by eLife, given the fundamental nature of several concerns, they also recommended that a revised manuscript should be evaluated by each reviewer.*

*1) The affinities and specificities of cholesterol binding to LAMP proteins is not adequately demonstrated.*

*It is concluded that 3H-cholesterol binds to LAMP2 with an affinity of Km \~ 5 µM. Given that the solubility of cholesterol in water is less than 100 nM, this result raises several critical questions. First, it is possible that a more soluble contaminant (e.g., an oxysterol) is responsible for the competition. Another possibility is that the cholesterol is in some type of micelle with the NP40 detergent. In either case, it is hard to know how to evaluate the concentration of cholesterol in these experiments. The authors need to elucidate the form of cholesterol that is bound by LAMP proteins.*

We agree with the reviewers that cholesterol affinities are difficult to measure and we clarified the text to explain this. We have used precisely the conditions employed by Brown & Goldstein in their studies of cholesterol binding to NPC1 protein.

New text: "Binding reactions were carried out in the presence of sub-critical micelle concentration concentrations of Nonidet P40 detergent to help solubilize the cholesterol (Infante et al., 2008). Under these conditions, most of the cholesterol remains in a mixed micelle of cholesterol and detergent and is still poorly soluble. Thus, the apparent affinity for cholesterol is likely to be tighter than the curves indicate, as the amounts added do not reflect the concentration of free cholesterol that is available for binding."

*The reviewers noted that the one-point competition experiments in [Figure 1G](#fig1){ref-type="fig"} are suggestive of specificity, but they agreed that it is essential to examine other structurally similar sterols (e.g., lanosterol), instead of cholesterol sulfate, which is more soluble than cholesterol. In addition, the competition data needs to show concentration curves of unlabeled competitor sterols.*

To better characterize the binding pocket we have now added a new [Figure 2](#fig2){ref-type="fig"}with complete binding profiles for cholesterol sulfate, 25-hydroxycholesterol, lanosterol and 7-ketocholesterol. Only 7-ketocholesterol and 25- hydroxycholesterol compete, consistent with our conclusion that the 3β-hydroxyl group of cholesterol enters the binding pocket.

*2) The lipid components of the membranes from which LAMP2 is purified and bound lipids identified ([Figure 2](#fig2){ref-type="fig"}) must be determined. It is key to evaluate the co-purification data in light of the abundances of cholesterol versus other abundant lipids in lysosomal membranes such as phospholipids and sphingolipids. 7-β-hydroxy cholesterol and 26-hydroxy-cholesterol are present at trace levels in cells when compared to cholesterol, and are not appropriate controls for this experiment.*

The protein is purified from secretions and not from membranes. A request for full lipid analysis is far beyond what Brown & Goldstein needed for NPC1 as a cholesterol binder. We added a new chromatogram to show that lanosterol, 24-, and 25-hydroxycholesterol also fail to co-chromatograph with the eluted material. Importantly, the mass peaks perfectly correspond to cholesterol or a derivative thereof, rather than a phospholipid or sphingolipid. Also, the binding specificity seen by competition (new [Figure 2](#fig2){ref-type="fig"}) is consistent with this. Finally, we sent our samples to Denny Porter and Chris Wassif at NIH who independently got the same profile that we did; they found no evidence of any phospholipids or special sterols.

*3) The conclusions that NPC1 and LAMPs bind each other and that this is regulated by cholesterol-dependent changes in oligomeric state of LAMP require additional support. Regarding the LAMP2-NPC1 binding experiment shown in [Figure 3C](#fig3){ref-type="fig"}, data should be shown for reactions carried out in the absence of cholesterol. It was noted that the primary data showing cholesterol dependence of binding shown in [Figure 3B](#fig3){ref-type="fig"} was not shown and further, that the approach does not afford sufficient control of cholesterol level to firmly support the authors\' conclusion that LAMP2 and NPC1 do not bind in the absence of cholesterol.*

We repeated the in vitro MST experiments with and without cholesterol and find that the N-terminal domain of NPC1 binds LAMP2 under either condition and now report this. We also added additional data in support of decreased interaction of LAMP2 with NPC1-GFP in cells with the addition of the actual gels (new [Figure 4](#fig4){ref-type="fig"} panel B). Thus, although the NPC1 N-terminal domain binds LAMP2 whether or not that NPC1 domain is occupied, the total proteins don't interact as well when cholesterol is limiting in lysosomes in cells.

*4) The reviewers had difficulty envisioning the role of LAMP proteins in NPC1,2-mediated cholesterol export from the lysosome as you suggest in the manuscript, and this requires serious consideration in the presentation of the proposed model. Specifically, previous work has suggested that NPC2 and NPC1-NTD bind cholesterol with opposite orientation of the hydroxyl, which would allow cholesterol to slide from one pocket to the other. If LAMPs and NPC1-NTD have the same orientation, this will not work; cholesterol would remain bound to LAMP. Related to this point, one reviewer raised the point that LAMPs seem better suited to be cholesterol sensors rather than \"reservoirs\". Compared to the capacity of the lysosome membrane to harbor cholesterol, are there really sufficient numbers of LAMP proteins per lysosome to constitute a \"reservoir?\"*

We actually went ahead and quantified the amount of LAMP and NPC1 proteins in cells using purified protein standards (new [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). The 3D LAMP2 concentration in 0.3mM which is not insignificant; it will be higher in 2D environment. We also clarified the Discussion to explain more clearly how LAMP proteins may hold soluble cholesterol for NPC2-mediated transfer to NPC1.

"...How might LAMP2's cholesterol binding site contribute to cholesterol export? Current models suggest that the soluble NPC2 protein binds cholesterol from the internal membranes of lysosomes and delivers it to NPC1 at the limiting membrane of this compartment (Kwon et al., 2009). \[...\] In future work, it will be important to elucidate precisely how LAMP2 interacts with both NPC2 and NPC1 to facilitate cholesterol export from lysosomes and how cholesterol binding contributes to LAMP2's other cellular roles."

\[Editors\' note: what now follows is the decision letter after the authors resubmitted for further consideration.\]

*Overall, the reviewers found this to be an interesting and potentially important study. However, lingering concerns with several fundamental aspects of the study drove the editor\'s decision. Regarding cholesterol binding by LAMP proteins, the reviewers acknowledged the encouraging data that supports this conclusion, but there remains concern with the methodology, including a suggestion for more rigorous controls for non-specific binding. There was agreement amongst the reviewers that a well-supported and fundamental advance regarding the mechanism of cholesterol export has yet to emerge the experiments that probed interactions between LAMP2 and NPC1 (and possibly NPC2), and also the data presented regarding LAMP2 oligomerization.*

*Reviewer \#1:*

*The authors have responded to each of the four major issues that were raised during the initial review. Each is addressed below.*

*\"1) The affinities and specificities of cholesterol binding to LAMP proteins is not adequately demonstrated.\"*

*New competition binding data ([Figure 2](#fig2){ref-type="fig"}) over a 50-fold concentration range (I think -- see below) show that 25-hydroxycholesterol and 7-ketocholesterol, but not cholesterol sulfate or lanosterol, compete with cholesterol for binding to secreted LAMP2 lumenal domain. The data, particularly for lanosterol, support the authors\' conclusion that the 3β position of cholesterol is recognized by LAMP2.*

Thank you. We have now added epicholesterol which is the best control for cholesterol specificity.

*The methods section needs to be updated. It is stated that competition experiments were done only in the presence of 30 μM unlabeled sterol.*

Corrected.

*\"2) The lipid components of the membranes from which LAMP2 is purified and bound lipids identified ([Figure 2](#fig2){ref-type="fig"}) must be determined.\"*

*The authors point out that the material that was analyzed was secreted LAMP2, not material extracted from a membrane. I\'m sorry -- my mistake for not appreciating this previously. This, and the additional mass spectra analyses provide further support that cholesterol is specifically recognized by LAMP2.*

Thank you and we have importantly clarified that there was no cholesterol in the medium.

*\"3) The conclusions that NPC1 and LAMPs bind each other and that this is regulated by cholesterol-dependent changes in oligomeric state of LAMP require additional support.\"*

*These concerns have been addressed with additional experiments.*

*The evidence presented in support of the conclusion that LAMP (LAMP1, in this case) dimerizes as a result of cholesterol depletion is an increase in the abundance of a high molecular weight species, consistent with a dimer, on a gel by anti-LAMP1 blot of cell extracts. Dimerization is one possibility. It could also be explained by an association with another protein, a conformational change, etc. While the magnitude in the increase in the putative LAMP1 dimer is statistically significant, it is a small proportion of the total LAMP1.*

We have removed this data.

*The IP in [Figure 4A](#fig4){ref-type="fig"} controls for co-IP of LAMP2 and NPC1-GFP, two integral membrane proteins, using just soluble GFP. A more appropriate and convincing control for specificity would be an unrelated GFP-tagged integral membrane protein.*

We have added the control lysosomal integral membrane protein, MCOLN1 and showed that it does not bind LAMP2.

*The authors now report that binding of purified LAMP2 and NPC1 N-term domain proteins is not affected by the presence or absence of cholesterol, though co-IP of the full length proteins from cells is diminished when cells are incubated with cyclodextrin. The authors also report that LAMP proteins are present in approx. 10-fold excess of NPC1, and that binding between the luminal domains of LAMP2 and NPC1 in vitro are not affected by cholesterol occupancy. Given the 5 nM KD affinity of the interaction measured in vitro, it seems most likely to me that they would be associated constitutively (meaning, in the presence of absence of cholesterol) in the lysosome membrane.*

Agreed (for the *N-terminus* which we measured in vitro, ± cholesterol); but in cells, the N-terminus may bind other things such as the rest of NPC1. The full length protein does show a difference in Co-IPs under different cholesterol concentrations.

*Overall, with regards to the mechanism, it\'s unclear to me what the data is telling us. Regardless of the mechanism, the data do support, in my opinion, the conclusion that LAMP2 plays a role in cholesterol efflux from the lysosome and that this is correlated with cholesterol binding to LAMP2.*

Thank you; the field needs new models to explain our findings.

*\"4) The reviewers had difficulty envisioning the role of LAMP proteins in NPC1,2-mediated cholesterol export from the lysosome as you suggest in the manuscript, and this requires serious consideration in the presentation of the proposed model.\"*

*With the clarification of the manner in which the authors use \"reservoir,\" along with the determination of LAMP protein abundance, I agree that it is plausible that LAMP proteins provide a physiologically relevant \"reservoir\" of cholesterol to be a component of the NPC1- and NPC2-mediated lysosomal cholesterol efflux pathway.*

Thank you.

*Reviewer \#2:*

*In general the authors have addressed my major concerns. However, I still have some questions and concerns that need to be addressed.*

*1) I don\'t understand the comment in the fourth paragraph of the Results and Discussion section. I don\'t see how having 25-OH cholesterol will improve the solubility of cholesterol and increase its binding.*

All the binding experiments use sub-CMC Triton to solubilize the sterol as worked out by Brown and Goldstein for the N-terminal domain of NPC1 (Infante et al. 2008 JBC 283, 1052). 25H is slightly more soluble than regular cholesterol, and all sterols come from mixed micelles onto LAMP protein in the binding reactions. Thus, there will be mixed micelles of 25H and regular cholesterol. We tried to clarify this in the text; (Infante et al. 2008 saw the same phenomena in the above paper in 3 figures).

*2) The treatment of wild type cells with cyclodextrin is confusing to me. Does it actually reduce cholesterol in the late endosomes/lysosomes?*

Yes, it does and it can cure the NPC phenotype of cholesterol accumulation (Maxfield (PNAS 107, 5477) and Brown/Goldstein now cited). This is now more clearly explained in the text.

*Without showing this, the effect on LAMP1 is hard to interpret. I am also concerned about the health of cells in LPDS and 1 mM CD for 24 hours.*

Brown and Goldstein showed that release of cholesterol from lysosomes, assayed by formation of cholesteryl esters, was maximal at 6 hours of treatment with 0.1% cyclodextrin (\~1mM); they also assayed 24hours in their time course (Abi-Mosleh et al. 2009 PNAS). We saw normal growth rate and no cell death after 24 hours. The text was modified to clarify this point, and added a toxicology reference that supports our findings.

*3) In the eighth paragraph of the Results and Discussion section. This explanation does not make sense to me. Only a small fraction of the LAMP is dimerized. There is still abundant monomer, which could interact with NPC1. I would recommend deleting the CD treatment and the LAMP dimerization. It is not key to the paper.*

Deleted as requested; such assays always capture only a small percent of oligomers in any case.

*Reviewer \#3:*

*In this revision, the authors have attempted to address the concerns raised with the cholesterol binding data and with their claims of cholesterol-regulated behavior of LAMP proteins and interaction with NPC proteins. Unfortunately, almost all of my concerns remain.*

*Specific points:*

*My previous review: "The assay showing direct binding of 3H-cholesterol to LAMP2 has no specificity controls ([Figure 1B](#fig1){ref-type="fig"}). Since 3H-cholesterol binding to LAMP2 shows weak affinity (Km \~ 5 µM), it is imperative to show that some other hydrophobic 3H-ligand does not bind to LAMP2 at these high concentrations where hydrophobic ligands often precipitate".*

Done (see below).

*"The one-point competition experiments in [Figure 1G](#fig1){ref-type="fig"} are suggestive of specificity, but the authors should try lanosterol (or some other structurally similar sterol) as a negative control, instead of cholesterol sulfate which is more soluble than cholesterol. The competition data also needs to show concentration curves of unlabeled competitor sterols. The authors\' claim of similar binding of cholesterol to LAMP2 and NPC1-NTD is misleading since they compare saturation stoichiometries, not the more relevant affinity parameters. To rule out non-specific binding of insoluble cholesterol to LAMP2, careful controls are needed".*

*The authors now say that they carried out binding reactions in the presence of sub-cmc concentrations of detergent. This sounds good, but the Methods section does not say anything about this. The only place the detergent is mentioned is in a new paragraph in the Results, but no details are given. All the binding data in [Figure 1](#fig1){ref-type="fig"} is identical to what was in the first submission. So, did the authors redo these with sub-cmc detergent and get the same results? In any case, even if the authors had merely not reported their experimental procedures accurately in the original submission, none of the concerns previously raised have been addressed.*

We have always used conditions established by Brown and Goldstein for NPC1 and explain that more clearly here. We thank the referee for helping us make this clearer.

*A) The key data is in [Figure 1B](#fig1){ref-type="fig"} which shows a saturation binding curve of 3H-cholesterol to LAMP2 that shows very weak affinity -- Km = 5-10 µM. This solitary curve is hard to interpret without carrying out the same dose curve in the presence of excess unlabeled cholesterol, which would indicate the background non-specific binding. Also, they need to show that some other 3H-sterol ligand does not bind LAMP2 in the same experiment. They claim later that 25-HC competes and lanosterol does not compete. Both of these sterols are available commercially in tritiated form. 3H-lanosterol would have been a great control for specificity.*

*B) The next key pieces of data are in 1G and 1H. Again, these panels are identical to the original submission, and once again it is not clear how much 3H-cholesterol was used. From extrapolation using 1B, it looks like around 5 µM, but details like these are critical and need to be indicated. In any case, 1H shows competition by unlabeled cholesterol, but there is no negative control with a non-competitor like cholesterol sulfate. The authors now add competition curves by other unlabeled sterols in [Figure 2](#fig2){ref-type="fig"}. Unfortunately, these cannot be judged because once again it is not clear how much 3H-cholesterol was used and the raw binding values that were normalized to 1.0 are not indicated. The authors should use cpm units so that we can compare with [Figure 1](#fig1){ref-type="fig"} data. Also, every competition curve in [Figure 2](#fig2){ref-type="fig"} requires a positive control and a negative control in the same experiment to be able to judge anything. They show competition curve for unlabeled cholesterol out to 15 µM in [Figure 1H](#fig1){ref-type="fig"}, but all the other competition curves are upto 50 µM -- what happens with unlabeled cholesterol at these concentrations. Based on the cholesterol data, the competitors should be judged by their ability to compete at 15 µM. Only 7-ketocholesterol seems to be a strong competitor. Also, why did they not do competition curves for 24-hydroxycholesterol, which according to [Figure 1G](#fig1){ref-type="fig"} was the strongest competitor? How about epicholesterol, where the 3-hydroxyl region is modified in a manner more subtle than cholesterol sulfate. The claim that the 3β-hydroxyl group of cholesterol enters the binding pocket cannot be made from these data.*

A ~3~H-lanosterol control would have cost \$2500. Instead we used the excellent suggestion of epicholesterol which wonderfully does not bind! (new [Figure 2C](#fig2){ref-type="fig"}, controls included). Thank you so much for this excellent suggestion. As noted by the referee, at high sterol concentrations, it is not possible to add enough competitor to fully block binding as there are significant solubility issues. Nevertheless, we have now made much more clear how the binding was done, how much cholesterol is present, and added new data for 25-hydroxycholesterol ± cold competitor (new [Figure 1C](#fig1){ref-type="fig"}). In summary, sterol binding is indeed specific and likely tighter than the apparent Kd due to solubility issues.

*C) The mass spec data showing cholesterol is present in purifications could be due to the high concentrations of cholesterol, but not their control sterols, in the serum-rich media into which the proteins were secreted. Again, no details of the growth conditions are given so that we can judge these results.*

Our error -- the protein was purified using Freestyle 293 medium lacking any cholesterol, thank you for catching our omission.

*My previous review: "The claim that LAMP proteins oligomerize when cholesterol is limiting and associate with NPC1 when cholesterol is available is not supported by the data of [Figure 3](#fig3){ref-type="fig"}. The association of NPC1 with LAMP2 is shown by IP in [Figure 3A](#fig3){ref-type="fig"}, but no cholesterol dependence for this interaction is shown (the raw data for the bar graph in 3B is not shown). Instead, the interaction of NPC1 with LAMP2 in the presence of cholesterol is shown by a different method in [Figure 3C](#fig3){ref-type="fig"}, but this experiment does not show what happens in the absence of cholesterol! [Figure 3G](#fig3){ref-type="fig"} shows a partial effect of cholesterol on LAMP1 dimerization, but not on LAMP2 oligomers. The key lane on the gel in [Figure 3G](#fig3){ref-type="fig"} is shown in isolation without any controls, so the significance of higher density of dimer is not clear. The quantification needs to be done on a gel from a single experiment with LAMP2".*

*The authors had previously claimed cholesterol dependency of NPC1-LAMP2 interaction, but had not shown the data in a single experiment. They now say that there is no cholesterol dependence, but again do not show the data!*

*The IP data showing interaction between LAMP2 and NPC1-GFP (a membrane protein) uses GFP (soluble protein) as a control. They would need to use another lysosomal membrane protein as a control to rule in specificity. Again, they claim that LAMP1 dimerizes using a gel where the key lane is shown in isolation without any controls ([Figure 4D, E](#fig4){ref-type="fig"}), so the significance of the slightly higher density of the dimer is not clear. The quantification needs to be done on a gel from a single experiment with LAMP1.*

We have added the control lysosomal integral membrane protein, MCOLN1 and

showed that it does not bind LAMP2. We did show the data for the quantitation and removed the crosslinking to avoid any issues.

*Eskelinen et al., 2004 and Schneede et al., 2011 have already highlighted the roles of Lamp2 in cholesterol transport, the key advance in this study is to attempt to show a direct interaction between cholesterol and LAMP proteins and to get at the mechanism. Neither of these points are supported by their data, and as such I do not think this paper makes a significant contribution to this problem.*

We feel strongly that the demonstration of direct cholesterol binding to LAMP2, its tight interaction with NPC1 in vitro and in cells, and the correlation between cholesterol binding capacity and phenotype rescue of LAMP depleted cells, represent a very unexpected and significant advance in our understanding of what role this protein family may play. Previous work provided no hints as to why LAMP1/2 depletion interfered with cholesterol export from lysosomes. Our work provides entirely new models that can be tested and studied further.
